HCC-1, a novel chemokine from human plasma by unknown
Brief Definitive Report 
HCC-1, a  Novel Chemokine from Human  Plasma 
By Peter Schulz-Knappe,*  Hans-Jiirgen  Miigert,* Beatrice Dewald,r 
Markus Meyer,*Yalcin Cetinfl Manfred Kubbies,It 
J6rg Tomeczkowski,￿82  Konstanze Kirchhoff,* Manfred Raida,* 
Knut Adermann,* Andreas Kist,* Manfred Reinecke,** 
P,.annar Sillard,* Andreas Pardigol,* Mariagrazia Uguccioni,a 
Marco Baggiolini,~:  and Wolf-Georg Forssmann* 
From the *Lower Saxony Institute for Peptide Research (IPF), D-30625 Hannover, Germany; the 
*  Theodor- Kocher Institute, University of Bern, CH-3012 Bern, Switzerland; the ~  Department 
of  Anatomy, Medical School, D-30625 Hannover, Germany, IIBoehringer Mannheim Ltd., D-82377 
Penzberg, Germany; the ￿82  of Pediatric Hematology and Oncology, Medical School, 
D-30625 Hannover, Germany; and the **Department of  Anatomy, University of Zurich, 
CH-8057 Ziirich, Switzerland 
Summary 
A  novel CC  chemokine,  HCC-1, was isolated from the hemoflhrate of patients with chronic 
renal failure. HCC-1  has a relative molecular mass of 8,673  and consists of 74 amino acids in- 
cluding four cysteines linked to disulfide bonds. HCC-1  cDNA was cloned from human bone 
marrow and shown to code for the mature protein plus a putative 19-residue leader sequence. 
Mature HCC-1  has sequence identity of 46% with macrophage inflammatory protein (MIP)-lc~ 
and  MIP-][3,  and 29-37%  with the other human  CC  chemokines.  Unlike  MIP-I~x and the 
other  CC  chemokines,  HCC-1  is  expressed  constitutively in  several normal  tissues  (spleen, 
liver, skeletal and heart muscle, gut,  and bone marrow),  and is present at high concentrations 
(1-80 nM)  in plasma. HCC-1  has weak activities on human monocytes and acts via receptors 
that also recognize MIP-lot. It induced intracellular Ca  2+  changes and enzyme release, but no 
chemotaxis, at concentrations of 100-1,000  nM, and was inactive on T  lymphocytes, neutro- 
phils,  and  eosinophil leukocytes.  In addition,  HCC-1  enhanced  the  proliferation of CD34 + 
myeloid progenitor ceils. It was as effective as MIP-lci, but about 100-fold less potent. 
H 
emofittration is a  routine treatment for patients with 
chronic  renal  failure  to  remove  substances  that  are 
normally cleared by the kidney. A  filter membrane  with a 
molecular mass  cut-off of 20  kD  is  used,  which  virtually 
excludes  plasma  proteins  (1,  2).  Being  available  in  large 
quantities, the hemoflltrate is an excellent source of biolog- 
ically active  human  peptides  that  circulate  in  the  blood. 
During the last 5  yr,  a  peptide bank was  established from 
>200,000  liters of hemofiltrate,  and  several peptide hor- 
mones were purified (1). During the course of a systematic 
search for novel bioactive factors (3), we have identified a 
new member of the recently recognized family of chemo- 
tactic  cytokines  (chemokines).  HCC-1  is  structurally  re- 
lated to macrophage inflammatory protein (MIP)-loc Un- 
like  MIP-lo~  and  the  other  CC  chemokines,  HCC-1  is 
highly  expressed  in  normal  tissues  and  is  present  at  high 
concentrations in human plasma. 
Materials and Methods 
Purification.  Peptides were extracted from batches of 2,000 li- 
ters of hemofiltrate by precipitation with 660 g/liter ammonium 
sulfate as described previously (2). The precipitate ("250 g) was 
dissolved in water (125  mg/ml). The peptides were precipitated 
again by addition of 4.5 vol of2-propanol, redissolved in 10 mM 
phosphate buffer, pH  3.0,  and fractionated by cation exchange 
chromatography (Fractogel TSK SP-650 M, 6  ￿  20 cm; Merck, 
Darmstadt, Germany) with a 0-1.0-M NaC1 gradient in the same 
buffer. Fractions eluting at high salt concentrations were collected 
and  further  purified by  preparative reverse-phase  (lkP)  HPLC 
(Parcosil  RP  C4,  300  ft,, 20-45  b~m, 3  ￿  12.5  cm;  Biotek, 
Oestringen,  Germany) using a gradient generated from 0.01  M 
HCI and 50% 2-propanol/30% methanol in 0.01  M HCI. Analyt- 
ical R.P  HPLC  (Parcosil RP  C4,  300  A, 5  btm,  1  ￿  12.5  cm, 
Biotek, Oestringen, Germany) was then performed using an ace- 
tonitrile/TFA gradient (0-80% acetonitrile in 0.1% TFA). 
Structure Analysis.  The  amino  acid  sequence  of the  native 
peptide and ofpeptide fragments obtained after cleavage with en- 
doproteinase Lys C  (EC 3.4.21.50)  and chymotrypsin (EC 3.4.21.1) 
was determined by Edman degradation analysis. The position of 
the cysteines was determined by amino-terminal sequencing of 
the fragments obtained after carboxamidomethylation and Lys C 
digestion. 
Mass spectrometry.  Molecular masses were determined using a 
Sciex API III triple stage quadrupole mass spectrometer (Perkin- 
Elmer Cetus Corp., Norwalk, CT) equipped with an electrospray 
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acid (vol/vol) and introduced via a syringe pump (Harvard Appa- 
ratus Ltd., Kent, UK) at a flow rate of 5 ~l/min. Measurements 
were performed in positive ion mode, and molecular masses were 
calculated from multiple protonated ions  using the  HyperMass 
program (Perkin-Elmer). 
Cloning of the HCC-I cDNA.  From 5  Ixg of human  adrenal 
gland  RNA,  cDNA  first  strand was  synthesized using MMLV 
RTase and an oligo(dT) primer (UNIP-2) complementary to the 
poly(A) tail ofeukaryotic mRNA. Using this primer and two de- 
generate sense primers (CC  1-1, CC  1-2)  derived from a partial 
HCC-1 amino acid sequence (see Fig. 2 B), a homogenous adre- 
nal gland cDNA fragment was amplified by a two-step PCR  (4) 
consisting of a 40-cycle amplification with CC 1-1/UNIP-2 fol- 
lowed by a 20-cycle amplification of 1/100th of the first mixture 
with CC 1-2/UNIP-2. The fragment was then cloned in pBlue- 
script (Stratagene, La Jolla, CA) and sequenced (5, 6).  A 234-bp 
DNA fragment was amplified from the recombinant plasmid and 
used as a probe for screening a human bone marrow cDNA li- 
brary  in  X  DR  2  (Clontech,  Palo  Alto,  CA).  From  positive 
clones, the  recombinant pDR  2  plasmids were  excised and se- 
quenced as described above. 
Bone Marrow Cells.  Human bone marrow mononuclear cells 
were  enriched  by  Ficoll-Hypaque centrifugation,  and  CD34 + 
cells were sorted using a FACStar  |  instrument (Becton Dickinson 
& Co., Mountainview, CA), defining the cells of interest within 
the  mononuclear population in  the  forward versus  side  scatter 
gate  exhibiting  FITC  (<CD34>),  but  not  PE  fluorescence 
(<CD14>).  Cultures were performed in 96-well plates (50 cells 
per well) with IMEM  medium containing 20%  human  plasma, 
penicillin/streptomycin, and several cytokines (rhSCF 20 ng/ml, 
rhlL-6 10 ng/ml, rhGM-CSF 100 ng/ml, and rhEPO  5 ng/ml). 
Cell numbers were assessed after 5 and 8 d using an image ana- 
lyzer (Quantimet Q  570;  Leica, Bensheim,  Germany) and after 
12  d by counting in a Neubauer chamber. Half of the medium 
was replaced after 6 d. 
Blood Cells.  Neutrophils,  eosinophils  and  monocytes  were 
prepared according to established methods (7-9). Cloned T lympho- 
cytes obtained from Dr. A. Lanzavecchia  (Basel Institute  of Immu- 
nology, Basel,  Switzerland) were assayed according to Loetscher 
et al. (10). Monocyte chemotaxis and enzyme release were assessed 
exactly as described by Uguccioni et al. (9), and changes of cyto- 
solic free calcium were determined according to von Tscharner et 
al. (11). 
Antisera.  A linear peptide corresponding to the amino-termi- 
nal domain ofHCC-1  (Thrl-Cys  16) and a multiple antigenic pep- 
tide consisting of a branched heptalysine core with eight copies of 
the  carboxyl-terminal  domain  of  HCC-I  (Asp62-Asn  TM)  co- 
valently bound were synthesized (12, 13), and antisera were raised 
in New Zealand white rabbits. 
RNA Expression.  Northern blot analysis was performed with 
total RNA from different human tissues using a 234-bp fragment 
of lice-1  cDNA (CC 1-3 to CC  1-4 in Fig. 2 B) as hybridiza- 
tion probe. For each tissue,  50 Ixg RNA was glyoxylated, sepa- 
rated in an agarose gel, transferred to nylon membrane, and hy- 
bridized (14) with the 32p-labeled 234-bp fragment. For reverse 
transcription PCR  analysis  (4),  a pair of highly specific primers 
(CC 1-3 and CC 1-4) was constructed from HCC-1 cDNA, and 
the reaction was performed with 1/30th of each cDNA synthe- 
sized from 5 Izg total RNA.  10-1*1 aliquots of the PCR reaction 
mixtures were taken after 25, 30, 35, and 40 amplification cycles, 
and were analyzed in a 1.5% ethidium bromide agarose gel. The 
fragments obtained were of the expected size of-'~  bp. 
Results  and  Discussion 
A  protein was purified from the crude peptide extract of 
2,000 liters ofhemofiltrate by cation exchange chromatog- 
raphy  followed by preparative  and  analytical RP-HPLC. 
As shown in Fig.  1,  the final product was homogenous,  as 
judged by capillary zone electrophoresis, and had a relative 
molecular  mass  of 8,673.  The  complete  sequence  of 74 
amino  acids  including  four  cysteines was  determined  by 
Edman  degradation  analysis  of the  native  protein  and  of 
peptide fragments obtained by proteolytic cleavage (Fig. 2 
A).  Analysis by mass spectrometry indicated that  the  cys- 
teines form  two  disulfide bonds.  A  search  for homology, 
which was performed in the Swiss-Prot, EMBL,  and gene 
bank data bases, showed that the sequence is new.  On the 
basis of sequence homology, molecular size, and the posi- 
tion of the four cysteines, it was concluded that the novel 
protein  represents  a  CC  chemokine  (15).  Since  it  was 
found in the hemofiltrate, it was termed HCC-1. 
HCC-1  shares 46% sequence identity with MIP-Icx and 
MIP-1[3.  The  overall  identity  is  29-37%  with  MCP-1, 
MCP-2,  MCP-3,  RANTES,  and  1-309,  but  only  16% 
with IL-8, a  CXC  chemokine.  The amino acid sequences 
of HCC-1  and MIP-1o~ are aligned in Fig. 2 A. Consider- 
able identity (61%)  is observed in the region between the 
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Figure  1.  Physicochemical char- 
actenzation of purified HCC-1. (A) 
Capillary zone  electrophoresis. (B) 
Electrospray mass spectrometry per- 
formed in  positive ion mode.  The 
mass of HCC-1 was calculated from 
the five multiple charged ions [M + 
4 HI  4+  to [M + 8 H]  a+. 
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5'  -  nontranslated region 
~GCrCCCAOCAGGOCAGCTCTCCTCCCACAACAGCTTCCCACAGC 
1 
A  I  P  F  F  L  L  I  T  I  A  L  G  T 
GCC ATT CCC TTC TTC CTC CTC ATC ACC ATC GCC CTA GGG ACC 
R  G  P  Y  H  P  S  E  C  C  F  T  Y  T 
CGG GGA CCT TAC CAC OCC TCA C~G TGC TGC TTC ACC TAC ACT 
--> 
--  CC 1-2  y> 
Q  R  I  M  D  Y  E  T  N  S  Q  C  S 
CAG CGG ATT ATG GAT TAC TAT (~G ACC AAC AGC C~G TGC TCC 
I  > coding region 
M  K  I  S  V  A 
ATG AAG ATC TCC GTG GCT 
mature HCC-I 
K  E  S  S  S 
AAG ACT GAA TCC TCC TCA 
-----  CC 1-1 --- 
T  Y  K  I  P  R 
ACC TAC AAG ATC CCG CGT 
CC I-3 -- 
K  P  G  I  V  F 
AAG OCC GGA ATT GTC TTC 
I  T  K  R  G  H  S  V  C  T  N  P  S  D  K  W  V  Q  D  Y 
ATC ACC AAA AGG GGC CAT TCC GTC TGT ACC AAC CCC AGT C~C AAG TGG GTC CAG GAC TAT 
132 
I--> 3' --  nontranslated  region 
I  K  D  M  K  E  N  STOP 
ATC AAG GAC ATG AAG GAG AAC TGAGTC~CCCAGAAGGGGTGG~GGCACAGCTCAGAC~CATAAAGAC,  AA  384 
polyadenylat ion  signal 
192  Figure 2.  Amino acid and nucleotide sequences.  (A) 
Purified HCC-1;  amino acid sequence and afignment 
with MIP lot.  Vertical  lines  indicate identical amino 
252  acids. The four cysteine residues are marked with aster- 
isks.  (/3) HCC-1  cDNA;  nudeotide  and  deduced 
amino acid sequence. The 5' nontranslated region con- 
312  sists of 54 bp, the coding region of 279 bp, and the Y 
nontranslated region of 148 bp. The positions and ori- 
entations of the PClk primers used are indicated by ar- 
rows.  The ATG start codon is marked by asterisks and 
the polyadenylation signal is underlined. The primers 
463  used are mdicated.  The sequence of the HCC-1 cDNA 
has been communicated to the EMBL database (acces- 
4~,8  sion No. Z49270). 
marrow  cDNA  library in  k  DR  2  using a  probe  that was 
amplified  from  adrenal  gland  cDNA.  Six  independent 
clones  were  isolated  and  the  insertions  of three  of them 
were  completely  sequenced.  The  5'  termini  of the  clones 
differed slightly in length, but the nucleotide sequences  of 
the overlapping regions were  identical.  The  first ATG  ap- 
pearing in the 5' to 3'  direction starts a  279-bp  open read- 
ing frame  that  totally  matches  the amino  acid sequence  of 
HCC-1  plus  an  amino-terminal  extension  of  19  residues 
with  the  characteristics  of a  leader  sequence.  The  largest 
<  CC I-4 
GATGCCAAC~CCCTCCTCCACCCACCCCTAACTCTCAGCCCCAGTCACCCTCTTGGAGCTTCCCTGC~TTAA 
<  UNIP-2 
AGACCACTCATGCTCT~8:A~  poly  (A)  tail 
first and the last cysteine.  The  amino-terminal  region pre- 
ceding  the  first  cysteine,  by  contrast,  differs  almost  com- 
pletely from MIP-lc~,  and is five residues  longer than that 
of MIP-le~ and all other known  CC  chemokines (15). This 
may be important with  regard to  the biological activity of 
HCC-1,  since it has been shown that amino-terminal trun- 
cation  drastically  affects  the  activity  of MCP-1  (16).  The 
length  of the amino-terminal  region  is also  critical for the 
activity of CXC  chemokines  (17). 
The  HCC-1  cDNA  was  cloned  from  a  human  bone 
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Figure  3.  Biological  activities.  (A) Cytosolic free  Ca  2+ changes  in human monocytes. Cross-desensitization  of the responses induced by 1,000  nM 
HCC-I and 30 nM RANTES or MIP-I~x. Monocytes isolated from donor blood were loaded with Fura-2 acetoxymethyl ester, and intracellular calcium 
changes were recorded. (B) Effect of HCC-1  on CD34 + human bone marrow cells. Comparison with MIP-loq TNF-la, and TGF-13. Cells numbers 
counted on day 12 are expressed in percent of control (mean -+ SEM). Four to eight separate experiments were performed with cells from different bone 
marrow donors. Significant difference from control (P <~ 0.05, two-tailed Student's t test) is indicated with an astensk, 
297  Schulz-Knappe  Brief Definitive Report Figure  4.  HCC-1  in plasma and tissues. (A) Detection of HCC-1 
by Western blotting. (Lanes 1-3)  Purified HCC-1 from hemofiltrate 
(50, 10, and 2 ng, respectively). (Lanes 4 and 5) 250 Ixl plasma from a 
healthy individual and a patient with chronic renal failure. (/3) Detec- 
tion of HCC-1  mP,.NA by Northern blotting, tkNA was extracted 
from spleen (lane 1), colon (lane 2), small intestine (lane 3), liver (lane 
4), heart muscle (lane 5), skeletal muscle (lane 6), kidney (lane 7), and 
brain (lane 8). 
cDNA insert  consisted  of 481  bp,  including a  putative  5' 
nontranslated region of 54 bp and a 3' nontranslated region 
of  148  bp  (Fig.  2  /3).  A  typical  polyadenylation  signal 
(AATTAAA) occurs  at  the  expected  distance  of ~20  bp 
from the poly(A)tail. 
In view of the structural relationship to CC chemokines, 
potential  biological  activities  of HCC-1  were  studied  on 
circulating  leukocytes  and  bone  marrow  cells.  HCC-1 
showed activity towards monocytes, as indicated by the rise 
of intraceilular  Ca  2+  at  100 nM or higher,  and a slight but 
significant release of N-acetyl-13-D-glucosaminidase at 1,000 
nM.  HCC-1,  however,  did not induce monocyte chemo- 
taxis at 0.1-1,000  nM  (data not shown).  Sequential  stimu- 
lation of monocytes with HCC-1  and related CC chemo- 
kines  was  used  to  assess cross-desensitization,  as  observed 
with  agonists  that  share  receptors.  As  shown  in  Fig.  3  A, 
MIP-lot and RANTES at 30 nM prevented responsiveness 
to  1,000 nM HCC-1,  while  1,000  nM  HCC-1  markedly 
decreased  the  response  to  30  nM  MIP-loL or  RANTES. 
HCC-1  was  also  tested  for stimulation  of T  lymphocytes 
and eosinophil and neutrophil leukocytes, but no cytosolic 
free Ca  2+ changes were detected. 
As shown in Fig.  3  B,  HCC-1,  like MIP-10I, enhanced 
the proliferation ofCD34 + cells.  The maximum effects ob- 
tained  with  HCC-1  (168%)  and  MIP-I~  (153%)  were 
comparable,  while  proliferation  was  inhibited  by  TNF-ot 
and TGF-[3 in  agreement with  previous reports  (18).  De- 
spite similar efficacy, HCC-1 was markedly less potent than 
MIP-la. Additional experiments using very early progeni- 
tor/stem  cells  (CD34+/CD38 -  bone  marrow  cells)  cul- 
tured in the presence of stem cell factor confirmed the pro- 
liferative  effect of HCC-1  and MIP-lo~  at  1,000  and  100 
ng/ml,  respectively.  It  was  reported  earlier  that  MIP-lot 
inhibits proliferation (19, 20), but recent studies, using pro- 
genitor/stem cell assays, which are more suited to assess cy- 
tokine  pleiotropy and  concentration  dependence,  indicate 
that MIP-lot stimulates very early as well as late committed 
CD34 + cells  (18, 21-23). 
Antisera against amino- and carboxyl-terminal regions of 
mature HCC-1  (see  Materials  and Methods)  were used for 
ELISA and Western blotting.  Determination in plasma and 
hemofiltrate  was  performed  after  solid-phase  cation  ex- 
change  extraction  of the  samples.  The  plasma  concentra- 
tions ranged between 2.5 and 80 nM (16.5  +  9.2, mean  --- 
SEM) in patients with chronic renal failure (n =  8), and 1.6 
and  10 nM  (5.6  +  1.3,  mean  +  SEM)  in healthy subjects 
(n  =  10).  These concentrations are surprisingly high com- 
pared  to  those  of other  chemokines,  which  are  normally 
undetectable  in  healthy  individuals  and  rarely  reach  high 
levels  even in  disease  (24,  25).  In plasma  samples  from all 
patients  and  healthy  controls  tested  so  far,  HCC-1  was 
readily detectable  by Western  blotting.  A  band of "~  kD 
was found in  every instance,  and no degradation products 
were apparent (Fig. 4 A). 
The  expression was studied  in several  tissues  by North- 
em  analysis.  Positive bands  of the  expected  size were  ob- 
tained with RNA  extracted from the spleen,  liver,  skeletal 
and  heart  muscle,  and  gut,  but  not  from  the  kidney  or 
brain  (Fig.  4  B).  Analysis  by  reverse  transcription  PCK 
(data  not  shown)  was  positive  for  the  spleen,  liver,  the 
hepatoma cell line HUH-7, skeletal and heart muscle, gut, 
and bone marrow.  A  faint band was obtained for the kid- 
ney, suggesting that some HCC-1  expression may occur in 
this tissue as well.  Since the tissues were considered normal 
and were not subjected to stimulation,  these results indicate 
that  HCC-1  is expressed constitutively in a variety of dif- 
ferent tissue ceils.  No expression was observed in the brain, 
blood leukocytes,  the monocytic cell lines,  THP-1,  U937, 
and HL-60, or in Jurkat cells. 
Chemokines have  some highly characteristic  properties: 
they are expressed in different tissues in response to inflam- 
matory stimuli (e.g., cytokines and bacterial toxins), are be- 
lieved to act locally rather than systemically, and have one 
major  effect,  the  activation  and  attraction  of leukocytes 
(15).  HCC-1  shares  marked  sequence  identity  and  some 
biological  activities  on  monocytes  and  myeloid precursor 
cells  with  MIP-lo~.  Certain  properties  of HCC-1,  how- 
ever, are not common for chemokines, namely, nanomolar 
concentration  in  plasma,  even  in  healthy  individuals,  and 
marked  expression  in  normal  tissues.  These  features  indi- 
cate  that  HCC-1  is  a  CC  chemokine  with  an  unconven- 
tional  bioactivity  profile.  Its  presence  in  plasma  suggests 
that it may exert  systemic effects on myeloid and possibly 
yet unknown target cells. 
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